No pressure on Keating. Been a director for 5 months.
Additionally, and following the filing, current Non-executive Director, Dr Tony Keating was appointed as Executive Director of the Company, to commence initially on a part time basis which followed the resignation of Dougal Thring as chief operating officer. Dr Keating was first appointed as Director of the Company on 5 December 2023 and is an experienced entrepreneur and CEO having co-founded and led ResApp Health from start-up to its ultimate acquisition by Pfizer for $180 million.
Improved chart
IMO
Ann: Appointment of Executive Director & FDA Pre-Ind Meeting, page-18
Add NSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.218M | |||
| Open | High | Low | Value | Volume |
| 4.4¢ | 4.4¢ | 4.2¢ | $5.582K | 131K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 49999 | 4.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 8637 | 1 |
View Market Depth
| Last trade - 16.10pm 27/05/2024 (20 minute delay) ? |
|
|||||
|
Last
4.2¢ |
Change
0.000 ( 4.55 %) |
||||
| Open | High | Low | Volume | ||
| 4.3¢ | 4.3¢ | 4.2¢ | 16400 | ||
| Last updated 15.54pm 27/05/2024 ? | |||||
| NSB (ASX) Chart |